The first Sarepta Therapeutics trade was made in Q2 2014.
Since then Steven Cohen bought shares 26 more times and sold shares on 35 occasions. The investor completely sold their stake between Q4 2023 and Q4 2023.
Avg closing price
Price range
Sold -307 Thousand shares
Q4 2023
Avg closing price
$95.93
Price range
$67.31
-
$124.76
Sold 6.7% shares (-22 Thousand shares)
Q3 2023
Avg closing price
$113.03
Price range
$102.50
-
$123.59
Increased shares by 579.7% (+281 Thousand shares)
Q2 2023
Avg closing price
$128.95
Price range
$106.40
-
$157.19
Sold 93.1% shares (-655 Thousand shares)
Q1 2023
Avg closing price
$129.72
Price range
$117.53
-
$155.99
Sold 17.4% shares (-148 Thousand shares)
Q4 2022
Avg closing price
$115.88
Price range
$100.39
-
$132.13
Increased shares by 100.2% (+426 Thousand shares)
Q3 2022
Avg closing price
$100.79
Price range
$75.71
-
$119.24
Sold 70.6% shares (-1.02 Million shares)
Q2 2022
Avg closing price
$73.57
Price range
$62.69
-
$88.44
Increased shares by 25.7% (+296 Thousand shares)
Q1 2022
Avg closing price
$76.58
Price range
$63.15
-
$90.42
Sold 37.6% shares (-695 Thousand shares)
Q4 2021
Avg closing price
$85.49
Price range
$77.28
-
$99.42
Increased shares by 341.0% (+1.43 Million shares)
Q3 2021
Avg closing price
$77.03
Price range
$65.97
-
$92.48
Increased shares by 201.2% (+280 Thousand shares)
Q2 2021
Avg closing price
$75.81
Price range
$69.38
-
$86.75
New holding (+139 Thousand shares)
Q1 2021
Avg closing price
$92.28
Price range
$72.25
-
$168.95
Sold -345 Thousand shares
Q1 2020
Avg closing price
$114.31
Price range
$82.38
-
$131.64
Sold 50.5% shares (-352 Thousand shares)
Q4 2019
Avg closing price
$100.93
Price range
$76.53
-
$135.58
New holding (+697 Thousand shares)
Q3 2019
Avg closing price
$118.10
Price range
$72.81
-
$156.91
Sold -261 Thousand shares
Q2 2019
Avg closing price
$121.53
Price range
$112.21
-
$151.95
Increased shares by 234.8% (+183 Thousand shares)
Q1 2019
Avg closing price
$128.56
Price range
$106.67
-
$151.68
Increased shares by 18.4% (+12.1 Thousand shares)
Q4 2018